




STANDARDIZED BIOLOGY PREDICTABLE DEVELOPMENT



COMPANY OVERVIEW

OUR MISSION

We support our partners **across the full drug discovery and development journey**, from preclinical research through clinical stages using our innovative micropattern platform

DISCOVERY PLATFORM

We provide **access to human primary cells and disease-relevant models** designed for high-throughput screening, supported by robust AI-powered image analysis

PROVEN TRACK RECORD

60+ projects with pharma & biotech companies worldwide



Created in 2008



25 Team members
75% of Scientists
(PhD & Engineers)




Located in **Grenoble, France**

CYTOO MICROPATTERNS A SOLUTION TO TRANSLATIONAL CHALLENGES

A key challenge in drug development is translating preclinical findings into clinical success

2D CELL CULTURE




Lacks **tissue complexity** to be physiologically relevant

IN VIVO



Limited **predictivity** due to physiological & genetic differences with humans


3D ORGANOID



Limited by **low throughput** and **high variability**

CYTOO

96- and 384-well plates,
>100 engineered mini-tissues per well (96w plates)



MICROPATTERNS – 2D

Optimal balance of **robustness** and **physiological relevance** across drug development, from screening to clinical translation

CYTOO'S TECHNOLOGY: BEST-IN-CLASS SOLUTION ACROSS DRUG DEVELOPMENT PATH

STEP OF DRUG DEVELOPMENT

Discovery & development

Preclinical research

Clinical research

Regulatory & Post-market

> 1B USD in development costs over 10 to 15 years





CYTOO micropatterning : Combine high physiological relevance with decrease variability and enhanced standardization to **accelerate development** and **reduce costs**



	CYTOO	2D models	3D organoids	In vivo
Throughput	+++	+++	+	+
Robustness	+++	++	+	+
Physiological relevance	++	+	+++	+++
Spatial information	+++	+++	+	+
Analysis Tools	+++	+	+	+
Transferable	+++	+++	++	+

MICROPATTERNS TO OVERCOME IN VITRO TISSUE DISORGANIZATION

CONVENTIONAL



CYT00





- FAST MATURATION
- MINIATURIZATION
- HIGH THROUGHPUT
- ACCURATE
- ROBUST
- RELIABLE

CYTOO's TECHNOLOGY

PREDICTIVE & COMPATIBLE WITH HCA

Primary human cells
Healthy & diseased donors

Micropatterns
Several tissue units per well




* Also compatible with standard biochemical techniques

Physiologically relevant
Disease models


Standardization
High statistical power

Automated, High throughput
Quantitative functional assay

AI-POWERED CELL PROFILING: MONITORING DISEASE REVERSAL WITH HEALTH-SCORE™




BIOBANKING CAPABILITIES



- Experience with primary culture to align preclinical discovery with clinical endpoints
- Capacity for immortalized cell line banking
- Skeletal muscle cells (primary myoblasts): 65+ donors banked across 10 disease indications with healthy controls
 - DMD, DM1, DM2, FSHD, Pompe Disease, SMA, PMM...
 - Metabolic disorders modeling through culture conditions
- Access through established collaborations with several biobanks


MICROPATTERN TECHNOLOGY FOR PREDICTIVE, PHYSIOLOGICAL MODELS




CO-CULTURE




SPHEROIDS



SINGLE CELL




CONTRACTILITY MEASURE




MYOSCREEN™

Striated Skeletal muscle platform



THE MYOSCREEN™ DISCOVERY PLATFORM

PREDICTIVE & COMPATIBLE WITH HCA



Scientifically validated (one primary human myoblasts donor): cytoo vs. conventional plates*

- High-speed & Physiologically relevant
 - **11-fold increase** in cell fusion after 24h
 - **Spontaneous AChR** clustering
 - **6x more** sarcomeric myotubes
- High robustness
 - **5x lower variability** in myotube size
 - **6000+ mini-muscles** per plate vs ~24/96 for 3D systems
 - **Increased dynamic range** of assay signal window
- Automated image analysis capabilities
 - Compatible with standard HCA systems
 - Free from user-related bias

*CYTOO paper: Young et al., SLAS Discov. 2018 doi: 10.1177/2472555218761102



Stefan DONEVSKI

CBO

sdonevski@cytoo.com

CYTOO SA – Headquarter
7 Parvis Louis Néel,
CS 20050 BHT – Bât. 52
38040 Grenoble cedex 9
France

Phone: +33 (0)4 38 88 47 05

Elie EL HACHEM

Business Development Director

eelhachem@cytoo.com

CYTOO SA – Secondary Office
16 Chemin du Vieux Chêne
38240 Meylan
FRANCE

